Fradet Y - Search Results

1

High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer.

Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y. Bergeron A, et al. Among authors: fradet y. Int J Cancer. 2009 Sep 15;125(6):1365-71. doi: 10.1002/ijc.24503. Int J Cancer. 2009. PMID: 19533752

2

Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder.

Fradet Y, Lafleur L, LaRue H. Fradet Y, et al. J Cell Biochem Suppl. 1992;16I:85-92. doi: 10.1002/jcb.240501319. J Cell Biochem Suppl. 1992. PMID: 1305695 Review.

3

Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas.

Fradet Y, LaRue H, Parent-Vaugeois C, Bergeron A, Dufour C, Boucher L, Bernier L. Fradet Y, et al. Int J Cancer. 1990 Dec 15;46(6):990-7. doi: 10.1002/ijc.2910460607. Int J Cancer. 1990. PMID: 1701166

4

Molecular and immunologic approaches in the management of bladder cancer.

Fradet Y. Fradet Y. Urol Clin North Am. 1991 Aug;18(3):515-24. Urol Clin North Am. 1991. PMID: 1877114

5

Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group.

Fradet Y, Tardif M, Bourget L, Robert J. Fradet Y, et al. Cancer Res. 1990 Jan 15;50(2):432-7. Cancer Res. 1990. PMID: 2295082

6

Growth-regulated surface glycoproteins of human bladder cancer.

Gauthier J, Fradet Y. Gauthier J, et al. Among authors: fradet y. Cancer Res. 1990 Jan 15;50(2):293-8. Cancer Res. 1990. PMID: 2403838

Clinical studies of human bladder cancer cells with mouse monoclonal antibodies (mAbs) have revealed two surface glycoproteins (T43 and T138) expressed by aggressive cancers and not by normal cells and a differentiation antigen (T16) expressed by normal and tumor cells of urothel …

Clinical studies of human bladder cancer cells with mouse monoclonal antibodies (mAbs) have revealed two surface glycoproteins (T43 and T138 …

7

Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies.

Fradet Y, Islam N, Boucher L, Parent-Vaugeois C, Tardif M. Fradet Y, et al. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7227-31. doi: 10.1073/pnas.84.20.7227. Proc Natl Acad Sci U S A. 1987. PMID: 3313389 Free PMC article.

8

Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer.

Ravery V, Colombel M, Popov Z, Bastuji S, Patard JJ, Bellot J, Abbou CC, Fradet Y, Chopin DK. Ravery V, et al. Among authors: fradet y. Br J Cancer. 1995 Jan;71(1):196-200. doi: 10.1038/bjc.1995.40. Br J Cancer. 1995. PMID: 7819039 Free PMC article.

9

Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer.

Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Tetu B, et al. Among authors: fradet y. J Urol. 1996 May;155(5):1784-8. J Urol. 1996. PMID: 8627884

10

Identification of a superficial bladder tumor-associated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211.

Bergeron A, LaRue H, Fradet Y. Bergeron A, et al. Among authors: fradet y. Cancer Res. 1996 Feb 15;56(4):908-15. Cancer Res. 1996. PMID: 8631032

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters